A Second Study of NicVAX/Placebo as an Aid for Smoking Cessation
Public ClinicalTrials.gov record NCT01102114. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Second Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy, Immunogenicity and Safety of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) as an Aid to Smoking Cessation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate NicVAX as an aid to smoking cessation for long term abstinence.
Study identification
- NCT ID
- NCT01102114
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,000 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2010
- Primary completion
- Oct 31, 2011
- Completion
- Oct 31, 2011
- Last update posted
- May 8, 2012
2010 – 2011
United States locations
- U.S. sites
- 25
- U.S. states
- 20
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| NicVAX Investigator | Encino | California | — | — |
| NicVAX Investigator | Los Alamitos | California | — | — |
| NicVAX Investigator | Denver | Colorado | — | — |
| NicVAX Investigator | New Haven | Connecticut | — | — |
| NicVAX Investigator | Brooksville | Florida | — | — |
| NicVAX Investigator | Orlando | Florida | — | — |
| NicVAX Investigator | Pembroke Pines | Florida | — | — |
| NicVAX Investigator | Tampa | Florida | — | — |
| NicVAX Investigator | Indianapolis | Indiana | — | — |
| NicVAX Investigator | Wichita | Kansas | — | — |
| NicVAX Investigator | Metairie | Louisiana | — | — |
| NicVAX Investigator | Annapolis | Maryland | — | — |
| NicVAX Investigator | Milford | Massachusetts | — | — |
| NicVAX Investigator | East Lansing | Michigan | — | — |
| NicVAX Investigator | Rochester | Minnesota | — | — |
| NicVAX Investigator | Jackson | Mississippi | — | — |
| NicVAX Investigator | Omaha | Nebraska | — | — |
| NicVAX Investigator | Buffalo | New York | — | — |
| NicVAX Investigator | Cincinnati | Ohio | — | — |
| NicVAX Investigator | Mt. Pleasant | South Carolina | — | — |
| NicVAX Investigator | Knoxville | Tennessee | — | — |
| NicVAX Investigator | Nashville | Tennessee | — | — |
| NicVAX Investigator | Houston | Texas | — | — |
| NicVAX Investigator | Salt Lake City | Utah | — | — |
| NicVAX Investigator | Charleston | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01102114, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 8, 2012 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01102114 live on ClinicalTrials.gov.